National Institute on Drug Abuse; Notice of Closed Meetings, 83508 [2024-23837]
Download as PDF
<![CDATA[
83508
Federal Register / Vol. 89, No. 200 / Wednesday, October 16, 2024 / Notices
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Division of Intramural
Research Board of Scientific Counselors,
NIAID.
Date: December 9–11, 2024.
Time: 8:00 a.m. to 10:15 a.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Address: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, Building 50, Conference Room 1227/
1233, 50 Center Drive, Bethesda, MD 20892.
Contact Person: Laurie Lewallen,
Committee Manager, Division of Intramural
Research, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, Building 33, Room 1N24, 33 North
Drive, Bethesda, MD 20892, 301–761–6362,
Laurie.Lewallen@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–23836 Filed 10–15–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Microglial Pathophysiology in Comorbid
Substance Use Disorder (SUD) and HIV.
Date: November 5, 2024.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
VerDate Sep<11>2014
16:43 Oct 15, 2024
Jkt 265001
Contact Person: Meysam Yazdankhah,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 402–6965,
meysam.yazdankhah@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanistic Studies on Social Behavior in
Substance Use Disorder.
Date: November 19, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of
Extramural Policy, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443–
4577, caitlin.moyer@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; High
Priority HIV and Substance Use Research.
Date: November 20, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Trinh T. Tran, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5843, trinh.tran@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
ACTION:
Dated: October 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
I. Public Participation
Interested persons are invited to
comment on this notice by submitting
written data, views, or arguments using
the method identified in the
aforementioned ADDRESSES section. All
members of the public including, but
not limited to, specialists in the field,
academic experts, members of industry,
public interest groups, and those with
relevant economic expertise are invited
to comment.
[FR Doc. 2024–23837 Filed 10–15–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. CISA–2024–0028]
Request for Comment on Product
Security Bad Practices Guidance
Cybersecurity and
Infrastructure Security Agency (CISA),
Department of Homeland Security
(DHS).
AGENCY:
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Notice of availability; request
for comment.
The Cybersecurity Division
(CSD) within the Cybersecurity and
Infrastructure Security Agency (CISA)
requests feedback on draft Product
Security Bad Practices guidance.
Additionally, CISA requests input on
analysis or approaches currently absent
from the guidance.
DATES: Written comments are requested
on or before December 2, 2024.
Submissions received after the deadline
for receiving comments may not be
considered.
ADDRESSES: You may submit comments,
identified by docket number CISA–
2024–0028, by following the
instructions below for submitting
comments via the Federal eRulemaking
Portal at https://www.regulations.gov.
Instructions: All comments received
must include the agency name and
docket number Docket Number CISA–
2024–0028. All comments received will
be posted without change to https://
www.regulations.gov, including any
personal information provided. CISA
reserves the right to publicly republish
relevant and unedited comments in
their entirety that are submitted to the
docket. Do not include personal
information such as account numbers,
social security numbers, or the names of
other individuals. Do not submit
confidential business information or
otherwise sensitive or protected
information.
Docket: For access to the docket to
read the draft Product Security Bad
Practices Guidance or comments
received, go to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Kirk
Lawrence; 202–617–0036;
SecureByDesign@cisa.dhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
II. Background
In line with CISA’s Secure by Design
initiative, software manufacturers
should ensure security is a core
consideration from the onset of software
development. CISA’s draft, voluntary
E:\FR\FM\16OCN1.SGM
16OCN1
]]>Agencies
[Federal Register Volume 89, Number 200 (Wednesday, October 16, 2024)]
[Notices]
[Page 83508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-23837]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Microglial Pathophysiology in Comorbid Substance Use
Disorder (SUD) and HIV.
Date: November 5, 2024.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institute of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Meysam Yazdankhah, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 402-6965,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanistic Studies on Social Behavior in Substance
Use Disorder.
Date: November 19, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institute of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Caitlin Elizabeth Angela Moyer, Ph.D.,
Scientific Review Officer, Scientific Review Branch, Office of
Extramural Policy, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-4577,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; High Priority HIV and Substance Use Research.
Date: November 20, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institute of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 827-5843, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: October 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-23837 Filed 10-15-24; 8:45 am]
BILLING CODE 4140-01-P
